Ben Reisman MD PhD

1K posts

Ben Reisman MD PhD banner
Ben Reisman MD PhD

Ben Reisman MD PhD

@BenjaminReisman

Onc Fellow @Hopkins_HemOnc via @OslerResidency + @VanderbiltMSTP • chemical biologist ⚗️

Baltimore, MD Katılım Ocak 2012
2.6K Takip Edilen1.1K Takipçiler
Ben Reisman MD PhD retweetledi
Matt Stier, MD, PhD
Matt Stier, MD, PhD@MattStier_ICU·
Now hiring a Postdoctoral Fellow in my lab at Vanderbilt. We study immunologic and metabolic dysfunction in human critical illness and sepsis. See flyer in the next post for details and how to apply. Come join our Nashville team! 🩸🦠🧪🏥 #Postdoc #Immunology #Sepsis
English
1
6
17
1.6K
Ben Reisman MD PhD retweetledi
Jamie Blundell
Jamie Blundell@jrblundell·
In 1999, Tom Maniatis discovered something remarkable: neurons achieve self-avoidance via stochastic methylation of the protocadherin gene cluster. We've just discovered this locus is an evolvable in-vivo barcode across the human tissues: biorxiv.org/cgi/content/sh… 🧵
English
6
67
183
25.2K
Ben Reisman MD PhD
Ben Reisman MD PhD@BenjaminReisman·
@EladSharonMD How do you get a large OS benefit (HR 0.5) without an accompanying a significant PFS benefit? Not just in this study, but conceptually I don't really understand this phenomenon. (Sipuleucel-T is another example in the prostate cancer world.)
English
1
0
0
83
Elad Sharon
Elad Sharon@EladSharonMD·
CTLA4!!! CTLA4!!! CTLA4!!!!
Masahiro TORASAWA, MD. PhD.@M_Torasawa

【Long-term Survival: Nivo+Ipi+Chemo vs Pembro+Chemo in advanced NSCLC】 🇯🇵 RWD (Japan): Multicenter Retrospective Study 💡Nivo+Ipi+Chemo (NICT) demonstrates superior long-term survival over Pembro+Chemo (PCT) in PD-L1 <1% NSCLC 📚Lung Cancer 2026 lungcancerjournal.info/article/S0169-… 🔑Key Results 👥 457 pts with advanced NSCLC treated with NICT or PCT were stratified by PD-L1 (<1% vs ≥1%) with >40 mos follow-up 📈 PD-L1 <1% Cohort: NICT significantly improved OS compared to PCT (Median OS: 47.4 mos vs 16.6 mos; HR 0.50, p=0.007) 🗓 Long-term Benefit: 3-year OS rates in the <1% group favored NICT (51.5% vs 28.2%, p=0.016) ⚖️ PD-L1 ≥1% Cohort: No significant difference in median OS (28.0 vs 28.4 mos) or PFS between regimens ☠️ Safety profiles were comparable (Grade ≥3 TRAEs, discontinuation, and TRD rates), though NICT had higher incidence of skin/pituitary toxicity

English
3
4
58
10.4K
Suraj Kannan
Suraj Kannan@TheSurajKannan·
Look, my physical exam skills have always been poor. But it's wild to me that whenever I ask a team "what's the pulsus" the only two responses I've gotten are "what's that" and "I don't know how to do that." Distributing that Stanford 25 vid would cut down my consults by 30%...
English
2
0
4
423
Ben Reisman MD PhD retweetledi
Mark Yarchoan
Mark Yarchoan@MarkYarchoan·
Ethan Neumann, a 27-year-old PhD candidate in my lab, devoted himself to studying #fibrolamellar carcinoma, the cancer that claimed his life last week. Please support his father’s effort to establish an endowed research fellowship in Ethan’s name ⬇️ gofundme.com/f/ethan-neuman…
Mark Yarchoan tweet media
English
107
1.7K
9.5K
220.1K
Ben Reisman MD PhD
Ben Reisman MD PhD@BenjaminReisman·
@JSheltzer Beautiful work as always, Jason! The ic50 (uM) looks to be on the higher side for “drug-like” but I suppose it’s acting more at the level of stoichiometry than Ki so perhaps that’s expected, is that your impression as well?
English
1
0
1
104
Ben Reisman MD PhD retweetledi
Matthew Villaume
Matthew Villaume@MVillaume·
Happy to get to share our work this year at ASH. Come by our oral on Sunday to learn how our novel F1 ATP synthase inhibitor kills AML cells and come by the poster on Monday to hear about why we think it effects AML metabolism very differently than other oxphos inhibitors #ASH25
Matthew Villaume tweet media
English
2
1
2
295
Ben Reisman MD PhD retweetledi
Mark Yarchoan
Mark Yarchoan@MarkYarchoan·
I doubted studies claiming ICI infusion timing mattered (ICI half-life = weeks!). Afternoon patients surely differ in unmeasurable ways. But now a randomized trial ➡️morning ICI does better… 🤔 asco.org/abstracts-pres…
English
6
3
27
9.5K
Ben Reisman MD PhD retweetledi
Conor McClune
Conor McClune@conor_mcclune·
Today in @Nature we report a systematic strategy to activate & identify gene sets in plants. We identify 8 new genes from the yew tree's Taxol biosynthetic pathway, enabling us to engineer tobacco with 17- & 20-gene pathways to Taxol precursors baccatin III and dBz-deoxy-Taxol. a thread 1/x.. nature.com/articles/s4158… With amazing coauthors @Sattely_lab @ctliu629 @fordycelab @Stanford_ChEMH @StanfordEng
English
5
55
269
35.5K
Ben Reisman MD PhD retweetledi
Mark Yarchoan
Mark Yarchoan@MarkYarchoan·
1/ Our new review is out today in Nature Reviews Cancer—on why therapeutic cancer vaccines are finally gaining traction after decades of setbacks. 🔗 rdcu.be/emkkd w/ @NeehaZaidi @DrLizJaffee Key takeaways below
English
2
7
22
1.8K
Ben Reisman MD PhD retweetledi
Kelsey Fisher-Wellman, PhD
Kelsey Fisher-Wellman, PhD@KFW_Lab·
📢 New KFW Lab paper out now in @ScienceAdvances! 📢 We show that AML cells resist chemotherapy by reversing the ATP synthase reaction—supporting oxidative metabolism and maintaining mitochondrial membrane potential. 🔬🧬 👉 science.org/doi/10.1126/sc…
English
6
30
80
4.9K
Ben Reisman MD PhD retweetledi
Cameron McAlpine
Cameron McAlpine@cam_phd·
We are delighted to share our latest findings today in @Nature. We describe cardiogenic regulation of sleep after cardiac injury. “Myocardial infarction augments sleep to limit cardiac inflammation and damage” nature.com/articles/s4158…
English
30
123
411
111.9K
Keith Hornberger
Keith Hornberger@KRHornberger·
Have been meaning to highlight this paper on macrolones for a while now — hitting bacteria on 2 targets to reduce resistance. While almost certainly not proximity inducers, there’s easy parallels between their structures and heterobifunctional degraders. nature.com/articles/s4158…
English
4
3
27
3.3K
Ben Reisman MD PhD
Ben Reisman MD PhD@BenjaminReisman·
@wgibson Really elegant work Will! It reminds me of the mechanism of leucovorin + 5FU, but the cell itself provides the missing 1/3rd of the ternary complex that confers sensitivity - what’s old is new again! Excited to see where you take this concept in p53 (and beyond?) 🚀
English
0
0
3
658
Ben Reisman MD PhD retweetledi
William Gibson
William Gibson@wgibson·
TP53: - Discovered 45 years ago, most cited gene all time - No therapies - 500 million people currently living will die of TP53 mutant cancers without new therapies Our Preprint: - A general strategy for TP53 missense mutant cancers (majority) with prototype small molecules
English
45
280
1.3K
390.8K

Keşfet

@EladSharonMD @CR_AACR @PCF_Science @AACR @hopkinskimmel @TheSurajKannan @JSheltzer @NatureMedicine